The latest announcement is out from Telo Genomics Corp ( (TSE:TELO) ).
Telo Genomics Corp has appointed Guido Baechler as the Executive Chairman of its Board of Directors, enhancing his role to provide strategic leadership in advancing the company’s machine-learning-driven 3D Telomere platform in oncology. This move is expected to support the company’s growth and commercialization efforts, particularly in the areas of multiple myeloma and prostate cancer. The company also announced stock option grants to insiders, employees, and consultants, and reported changes in its board and management team.
More about Telo Genomics Corp
Telo Genomics is a biotech company specializing in diagnostic and prognostic tests through the analysis of chromosomal telomeres. The company focuses on applications in oncology and neurological diseases, particularly in the development of liquid biopsies and related technologies.
YTD Price Performance: 4.17%
Average Trading Volume: 48,155
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: C$12.48M
Find detailed analytics on TELO stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com